Recently, we also established that a low NLR could predict the progression-free survival (PFS) benefit in NSCLC patients with high PD-L1 expression who received combination therapy compared to those receiving only ICIs (15). This evidence concerns the gene CD274 and non-small cell lung carcinoma.